10月29日晚间，普蕊斯（301257）披露2025年三季报，报告期内，公司实现营业收入6.09亿元，同比增 长2.59%；净利润8738.15万元，同比增长20.92%；实现归属于上市公司股东的扣除非经常性损益的净利 润6967.44万元，同比增长11.48%，主要是由于公司持续落地的精细化运营管理措施所致。 据普蕊斯三季报，截至报告期末，公司员工总数为4271人，专业的业务人员4000余人，累计服务960余 家临床试验机构，临床试验机构可覆盖能力为1300余家，服务范围覆盖全国200余个城市，能够满足客 户绝大多数项目需求。截至报告期末，公司累计承接超过4200个国际和国内SMO项目，在执行SMO项 目2538个。 此前，普蕊斯在今年9月份的机构调研中介绍，上半年行业和客户需求呈现复苏的迹象，公司询单数量 同比实现较快增长，公司新签不含税合同金额6.00亿元，同比增长40.12%，订单增加主要由于国内外制 药企业的新药临床试验对SMO服务的需求增加所致。截至2025年6月末，公司存量不含税合同金额为 19.98亿元，同比增长9.45%。 提及公司业务合同平均多少时间可以转化确认为收入，普蕊斯表示，临床试验 ...

Group 1: Industry Overview - The pharmaceutical and biotechnology sector is experiencing a rebound, with innovative drug concept stocks showing volatility and recovery, exemplified by the stock price of Puris (301257) reaching a limit up of 43.54 yuan per share [1] - A national meeting on the "14th Five-Year" pharmaceutical planning emphasized the need for comprehensive drug safety systems, regulatory reforms, and the promotion of high-quality development in the pharmaceutical industry [3] - According to Guojin Securities, China's innovative drug industry has entered a phase of comprehensive harvest, becoming a global center for new drug development with the highest number of pipelines in the world [3] Group 2: Company Profile - Puris is a data-driven clinical research service provider focused on enhancing the efficiency and quality of clinical trials for global pharmaceutical companies and CROs, with collaborations with major international and domestic innovative pharmaceutical companies [4] - The company reported a 1.82% year-on-year increase in its main revenue for Q2, amounting to 214 million yuan, and a 45.17% increase in net profit attributable to shareholders, reaching 46.72 million yuan [5] - As of the end of Q2, Puris has served over 960 clinical trial institutions, with coverage capabilities extending to over 1,300 institutions across more than 200 cities in China [5]